推薦產品
等級
pharmaceutical primary standard
API 家族
etidronate
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
InChI
1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
InChI 密鑰
GWBBVOVXJZATQQ-UHFFFAOYSA-L
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Etidronate disodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Determination of etidronate disodium tablets by ion chromatography with indirect UV detection.
Tsai E W, et al.
Journal of Pharmaceutical and Biomedical Analysis, 11(6), 513-516 (1993)
S M Krane
Annals of internal medicine, 96(5), 619-625 (1982-05-01)
Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with
The role of risedronate in osteopenia in Crohn's disease.
Alice Buchan et al.
Gut, 64(1), 185-185 (2013-12-07)
Ivana Sestak et al.
The Lancet. Oncology, 15(13), 1460-1468 (2014-12-03)
Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed effectiveness of oral risedronate for prevention of reduction in bone mineral density (BMD) after 3 years of
Jörg Schilcher et al.
Acta orthopaedica, 86(1), 100-107 (2015-01-15)
Use of bisphosphonates in women is associated with higher risk of atypical femoral fractures. The risk in terms of timing of use and type of bisphosphonate, and in men, remains unclear. We reviewed radiographs of 5,342 Swedish women and men
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務